Antidepressants for depressed patients with type 2 diabetes mellitus: A systematic review and network meta-analysis of short-term randomized controlled trials
Antidepressants for depressed patients with type 2 diabetes mellitus: A systematic review and network meta-analysis of short-term randomized controlled trials
复制标题
抗抑郁药治疗 2 型糖尿病抑郁症患者：短期随机对照试验的系统评价和网络荟萃分析
DOI：
10.1016/j.neubiorev.2022.104731
复制
发表时间：
2022
影响因子：
8.2
通讯作者：
B. Maneeton
中科院分区：
文献类型：
--
作者：
M. Srisurapanont;S. Suttajit;N. Kosachunhanun;S. Likhitsathian;Chawisa Suradom;B. Maneeton
该网络荟萃分析比较了不同抗抑郁药对2型糖尿病（T2DM）抑郁症患者抑郁严重程度和HbA1c的短期治疗效果。我们于2021年11月22日在PubMed、Scopus、Web of Science、Cochrane Central Register of Controlled trials和Clinicaltrials.gov中检索了8- 24周的随机对照试验（RCTs）。我们纳入了12项随机对照试验（N = 792），研究阿戈美拉汀、西酞普兰、艾司西酞普兰、氟西汀、去甲替林、无治疗、帕罗西汀、舍曲林、沃替西汀和安慰剂。与安慰剂相比，抑郁严重程度降低的标准化平均差异和95%可信区间（SMD, 95% ci）显示，艾司西酞普兰排名第一（- 2.93,- 3.92至- 1.94），其次是阿戈美拉汀（- 0.68,- 1.15至- 0.20）。与安慰剂相比，降低HbA1c的平均差异（MDs, 95% ci）表明沃替西汀排名第一（- 2.35,- 4.13至- 0.57），其次是艾司西酞普兰（- 1.00,- 1.42至- 0.57）和阿戈美拉汀（- 0.79,- 1.16至- 0.42）。在伴有2型糖尿病的抑郁患者中进行的短期试验中，有限的证据表明艾司西酞普兰和阿戈美拉汀可能在降低抑郁和控制血糖目标方面具有良好的效果，但还需要更多的试验。
This network meta-analysis compared the short-term treatment effects of different antidepressants on depression severity and HbA1c in depressed patients with type 2 diabetes mellitus (T2DM). We searched 8- to 24-week randomized-controlled trials (RCTs) in PubMed, Scopus, Web of Science, Cochrane Central Register of Controlled Trials, and Clinicaltrials.gov on November 22, 2021. We included 12 RCTs (N = 792) studying agomelatine, citalopram, escitalopram, fluoxetine, nortriptyline, no treatment, paroxetine, sertraline, vortioxetine, and placebo. Compared to placebo, the standardized mean differences and 95% confidence intervals (SMD, 95%CIs) for depression severity reduction revealed that escitalopram ranked first (−2.93, −3.92 to −1.94), followed by agomelatine (−0.68, −1.15 to −0.20). Compared to placebo, the mean differences (MDs, 95%CIs) for HbA1c reduction suggested that vortioxetine ranked first (−2.35, −4.13 to −0.57), followed by escitalopram (−1.00, −1.42 to −0.57) and agomelatine (−0.79, −1.16 to −0.42). Limited evidence from short-term trials in depressed patients with T2DM suggests that escitalopram and agomelatine may have a favorable profile in reducing depression and controlling glycemic goals, but more trials are required.